Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation by Gatei, Magtouf et al.
Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent
Phosphorylation of Chk1 on Ser-317 in Response to
Ionizing Radiation*
Received for publication, October 23, 2002, and in revised form, February 13, 2003
Published, JBC Papers in Press, February 14, 2003, DOI 10.1074/jbc.M210862200
Magtouf Gatei‡, Katie Sloper‡, Claus So¨rensen§, Randi Syljua¨sen§, Jacob Falck§,
Karen Hobson‡, Kienan Savage‡, Jiri Lukas§, Bin-Bing Zhou¶, Jiri Bartek§,
and Kum Kum Khanna‡
From the ‡Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Brisbane, Queensland 4029,
Australia, the §Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100, Copenhagen,
Denmark, and ¶Incyte Genomics, Newark, Delaware 19714
In mammals, the ATM (ataxia-telangiectasia-mutated)
and ATR (ATM and Rad3-related) protein kinases func-
tion as critical regulators of the cellular DNA damage
response. The checkpoint functions of ATR and ATM are
mediated, in part, by a pair of checkpoint effector ki-
nases termed Chk1 and Chk2. In mammalian cells, evi-
dence has been presented that Chk1 is devoted to the
ATR signaling pathway and is modified by ATR in re-
sponse to replication inhibition and UV-induced dam-
age, whereas Chk2 functions primarily through ATM in
response to ionizing radiation (IR), suggesting that
Chk2 and Chk1 might have evolved to channel the DNA
damage signal from ATM and ATR, respectively. We
demonstrate here that the ATR-Chk1 and ATM-Chk2
pathways are not parallel branches of the DNA damage
response pathway but instead show a high degree of
cross-talk and connectivity. ATM does in fact signal to
Chk1 in response to IR. Phosphorylation of Chk1 on
Ser-317 in response to IR is ATM-dependent. We also
show that functional NBS1 is required for phosphoryla-
tion of Chk1, indicating that NBS1 might facilitate the
access of Chk1 to ATM at the sites of DNA damage.
Abrogation of Chk1 expression by RNA interference re-
sulted in defects in IR-induced S and G2/M phase check-
points; however, the overexpression of phosphorylation
site mutant (S317A, S345A or S317A/S345A double mu-
tant) Chk1 failed to interfere with these checkpoints.
Surprisingly, the kinase-dead Chk1 (D130A) also failed
to abrogate the S and G2 checkpoint through any obvi-
ous dominant negative effect toward endogenous Chk1.
Therefore, further studies will be required to assess the
contribution made by phosphorylation events to Chk1
regulation. Overall, the data presented in the study
challenge the model in which Chk1 only functions down-
stream from ATR and indicate that ATM does signal to
Chk1. In addition, this study also demonstrates that
Chk1 is essential for IR-induced inhibition of DNA syn-
thesis and the G2/M checkpoint.
The detection of DNA damage in mammalian cells induces
an array of responses that result in cell cycle arrest, DNA
repair, gene transcription, and, in some instances, cell death
(1). In mammals, the ataxia-telangiectasia-mutated (ATM)1
and ATM and Rad3-related (ATR) protein kinases function as
critical regulators of the cellular DNA damage response. ATM
and ATR are Ser/Thr-Gln-directed protein kinases with over-
lapping substrate specificities that are activated in response to
distinct as well as partially overlapping types of genotoxic
stimuli (2, 3). Despite their structural similarity and overlap-
ping substrate specificities, ATR and ATM are functionally
non-redundant protein kinases. Cells from A-T patients or
ATM-nullizygous mice are exquisitely sensitive to ionizing ra-
diation (IR) and other agents that induce double strand breaks
and are defective in activating IR-induced G1/S, S phase, and
G2/M checkpoints (4, 5), whereas checkpoint responses to UV
light and base-damaging agents are normal in A-T cells. In
contrast to ATM/ mice, which are viable, ATR-deficient mice
die early during embryogenesis, and the conditional knockout
of ATR gene function in human cells leads to a loss of cellular
viability (6–8). ATR is required for the G2/M DNA damage
checkpoint as well as the DNA replication checkpoint, which
suppresses mitosis in the presence of unreplicated DNA (9).
ATR mediates responses to a broad spectrum of genotoxic stim-
uli, including IR, DNA replication inhibitors (e.g. hydroxyurea
or HU), UV light, and agents such as cis-platinum that induce
DNA inter-strand crosslinks (9, 10). A common denominator of
these agents is the ability to induce transient or prolonged
DNA replication fork stalling during S phase. This stalled
replication fork may be a critical trigger for ATR signaling
potential.
The checkpoint functions of ATR and ATM are mediated, in
part, by a pair of checkpoint effector kinases termed Chk1 and
Chk2/Cds1 (1, 2, 3). Although structurally distinct, Chk1 and
Chk2 are functionally related kinases that phosphorylate an
overlapping pool of cellular substrates (11). In mammalian
cells, evidence has been presented that Chk2 and Chk1 have
apparently evolved to channel DNA damage signals from ATM
and ATR, respectively. This is based on reports that Chk1
appears to be devoted to the ATR signaling pathway and is
modified by ATR in response to replication inhibition and UV-
induced damage, whereas Chk2 functions primarily through
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ATM in response to IR (12–14). Here, we have investigated the
contribution of ATM in the regulation of Chk1 after IR. We
demonstrate that Chk1 is a downstream target of ATM and is
phosphorylated on Ser-317 in response to IR. Reduction of
Chk1 expression by RNA interference results in a defect in
regulation of the S and G2 phase checkpoints; however cells
overexpressing the phosphorylation site mutants Chk1 were
not compromised in their ability to arrest in S and G2
following IR.
MATERIALS AND METHODS
Cell Lines, Lysate Preparation and Immunoblotting—Control, A-T,
and NBS lymphoblastoid cell lines were grown in RPMI 1640 with 10%
fetal calf serum, 100 units/ml penicillin, and 100 g/ml streptomycin.
Cells were exposed to genotoxic agents (gamma, UV radiation, or HU)
and, unless otherwise stated, harvested at the indicated time points.
Cell extracts were prepared by lysis in universal immunoprecipitation
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 25 mM
sodium fluoride, 25 mM -glycerophosphate, 0.1 mM sodium orthovana-
date, 0.1 mM phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, 1 g/ml
aprotinin, 0.2% Triton X-100, and 0.3% Nonidet-P40). Twenty-five mi-
crograms of whole cell extract was loaded per lane on 7.5% SDS-PAGE
gels. Samples were transferred to nitrocellulose using carbonate buffer
at 30 V for 3 h, and the membranes were probed with appropriate
antibodies.
Rabbit polyclonal anti-phosphopeptide antisera against ATM/ATR
phosphorylation sites in Chk1 (Ser-317 and Ser-345) were raised by
immunizing rabbits with the keyhole limpet hemocyanin-conjugated
phosphopeptides NVKYSS-PhosphoSer-QPEPRT (for Ser-317) and
VQGISF-PhosphoSer-QPTCPD (for Ser-345). Bleeds were assayed by
enzyme-linked immunosorbent assay, and the serum was collected on
days corresponding to the peak antibody response and affinity purified
against the same peptide. Anti-Chk1 monoclonal and anti-cyclin B
antibodies were from Santa Cruz Biotechnology, and anti-S15p53 was
from New England Biolabs.
Plasmid Constructs and siRNA Oligos—ATM-complemented cells
(15) and NBS1-complemented (16) cells have been described previously.
Kinase-dead Chk1 (D130A, D148E), phosphorylation site Chk1 mu-
tants (S317A, S345A, S317A/S345A, S317D, S345D, S317D/S345D)
were constructed using the Quick Change mutagenesis kit (Stratagene)
by using FLAG-tagged Chk1 in PCI-Neo vector (Promega) as a tem-
plate. The details of the primers are available from the authors on
request.
RNA interference of Chk1 was performed using 5-UCGUGAGC-
GUUUGUUGAAC-3. siRNA specific to HSP70 served as a negative
control (GCACAUCAGCCAGAACAAG). The oligos were purchased
from Dharmacon Research, Boulder, CO. A siRNA duplex was annealed
using the protocol supplied by the company, and transfection was car-
ried out using the OligofectAMINE reagent (Invitrogen) according to
the manufacturer’s recommendations. Cell lysates were prepared 48 h
after transfection.
Synchronization of Cells—Cells were synchronized by double thymi-
dine block (17). Briefly, 2.5 mM thymidine was added for 16 h, cells were
washed twice with phosphate-buffered saline and released in fresh
media containing 24 M thymidine and 24 M deoxycytidine for 10 h.
Cells were reblocked in 2.5 mM thymidine for 16 h. At this point, the
cells were washed twice with phosphate-buffered saline and placed into
normal medium. This point was designated t 0, the point at which 80%
of cells are in G1/S by propidium iodide-flow cytometry analysis,
and cells were harvested at 4 h (mid S phase), 7 h (G2 phase), and 9.5 h
(G2  M phase). At each time point the cells were either left untreated
or treated with 6 Gy of IR for 30 min. Total cell extracts were prepared
as described above and blotted with the respective antibodies.
G2/M Checkpoint—Cells were mock transfected or transfected with
various Chk1 constructs or Chk1 siRNAs. Forty-eight hours later, cells
were mock irradiated or exposed to 3 Gy of IR. Cells were harvested 1 h
after IR and fixed in 70% ethanol at 20 °C. After centrifugation, the
cell pellet was suspended in 100 l of phosphate-buffered saline con-
taining 0.25 g of phospho-histone H3 antibody and 1% bovine serum
albumin followed by staining with a fluorescein isothiocyanate-labeled
secondary antibody as described previously (18). After 1 h of incubation
at room temperature in the dark, the cells were stained with phosphati-
dylinositol, and cellular fluorescence was measured by BD Biosciences
FACScan. The data was analyzed using Cell Quest software.
Intra-S Phase Checkpoint—Suppression of DNA synthesis after DNA
damage was assessed as described (19). Cells were labeled with 10 nCi
of [14C]thymidine for 24 h. The isotope was then washed away during
the transfection procedure, and the cells were transiently transfected
with siRNA oligos Chk1 or co-transfected with pCMV CD-20 and vari-
ous Chk1 constructs at the ratio of 1:10 and incubated without [14C]thy-
midine for 24 h. Cells were then irradiated with 10 Gy, and, 45 min
post-irradiation, [3H]thymidine (2.5 Ci/ml) was added. Fifteen min-
utes after the addition of [3H]thymidine, cells were harvested and fixed
in 70% methanol either directly or after isolation with anti-CD-20-
coupled Dynabeads as described (19), and radioactivity was measured
in an liquid scintillation counter. The DNA synthesis was estimated by
the ratios of 3H to 14C and expressed as a percentage of control values.
RESULTS
Chk1 Ser-317 Phosphorylation Is Defective in ATM- and
NBS-deficient Cells—To delineate the relationship between
ATM and Chk1, we studied Chk1 mobility shift in control and
AT cells treated with IR. In control lymphoblastoid cells
(C3ABR and C2ABR), a small fraction of the Chk1 protein from
IR-treated cells showed a reproducible reduction in mobility
compared with untreated cells, whereas most of the AT cell
lines (L3, AT1ABR, AT3ABR) tested failed to show that shift in
mobility (Fig 1A). Chk1 modification post UV irradiation was
quite comparable in AT and control lymphoblastoid cell lines
(Fig. 1A). Previous studies have shown that this modification of
Chk1 after DNA damage is because of phosphorylation. There-
fore, we examined the in vivo phosphorylation status of Chk1 in
AT and control cells with or without prior exposure to irradia-
tion. AT and control cells were metabolically labeled with 32P
for 2 h immediately after exposure to 6 Gy of irradiation. Chk1
was immunoprecipitated from the cell lysates and fractionated
by 10% SDS-PAGE, and radiolabeled Chk1 was detected by
autoradiography. Chk1 in non-irradiated control and A-T cells
appears to be already phosphorylated, and this phosphoryla-
tion was greatly enhanced (3-fold) 2 h after IR in control cells.
In contrast, there was a barely detectable increase in 32P-
labeled Chk1 from IR-treated AT cells (Fig. 1B). Earlier studies
have mapped two damage-induced sites (Ser-317 and Ser-345)
of phosphorylation in Chk1, and ATR has been shown to phos-
phorylate Chk1 on Ser-345 and Ser-317 primarily in response
to replication inhibition and UV (12, 14). Therefore, to examine
Chk1 phosphorylation we generated rabbit polyclonal antibod-
ies against a synthetic polypeptide consisting of phosphoryl-
ated Ser-317 or Ser-345. We were unable to detect Ser-345
phosphorylation of Chk1 in response to IR in lymphoblastoid or
fibroblast cell lines from control individuals. However, signifi-
cant phosphorylation of Ser-317 in Chk1 was observed in re-
sponse to various damaging agents in control cells. A-T cells
were defective in rapid phosphorylation of Chk1 on Ser-317 in
response to IR (6 or 10 Gy), but at a high dose of IR (20 Gy) or
after HU and UV, Chk1 phosphorylation in AT and control cells
was quite comparable (Fig 1C, top panel). The extent of phos-
phorylation of Chk1 was quite comparable with the phospho-
rylation of p53, a widely accepted target of ATM (Fig 1C,
bottom panel). The time course analysis revealed that Chk1
phosphorylation was induced in control cells within 30 min
post-IR (6 Gy), whereas in ATM-deficient cells it became evi-
dent by 2 h and was still markedly reduced compared with
controls at 6 h after IR (Fig. 1D). Defective IR-induced Chk1
phosphorylation in A-T cells was corrected by the introduction
of ATM cDNA; therefore, it is indeed ATM-dependent (Fig. 1E).
Ser-317 phosphorylation of Chk1 was also defective (Fig. 1F) in
lymphoblastoid cells derived from individuals either homozy-
gous or heterozygous for ATM mutation (T7271G), which is
known to confer a high risk of breast cancer (20, 21). We have
shown previously that this mutant form of ATM is quite stable
but intrinsically defective as a kinase (21). The mutant allele
has been shown to act as a dominant negative manner so that
the wild-type ATM is unable to function in the presence of
Phosphorylation of Chk1 on Ser-317 in Response to IR 14807
 at UQ Library on September 2, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
mutant protein. The defective Ser-317 phosphorylation in a
heterozygous carrier of T7271G mutation is related to this
dominant negative effect (Fig. 1F).
Evidence from yeast and vertebrate systems has shown that
the activation of Chk1 and Chk2 requires a large number of
additional gene products that participate in the detection, ini-
tiation, and propagation of checkpoint signals (22). Addition-
ally, radiation-induced phosphorylation of certain ATM sub-
strates such as SMC1 has been reported to be defective in NBS
cells (23, 24), whereas phosphorylation of others (p53, BRCA1,
and Rad9) has been reported to occur normally in NBS cell
lines (16, 25). Therefore, we examined the dependence of Chk1
phosphorylation on NBS1. Dramatically reduced phosphoryla-
tion of Chk1 in response to IR was also observed in cells
deficient in NBS1 as compared with control cells (Fig. 2A), but
after HU and UV, Chk1 phosphorylation in NBS1-deficient
cells and control cells was comparable (Fig. 2B). Phosphoryla-
tion of Chk1 was restored with the introduction of NBS1 cDNA
in NBS-deficient fibroblasts (Fig 2C). NBS1 is a target of ATM,
and ATM phosphorylates NBS1 on Ser-343. This phosphoryla-
tion is required for activation of the S phase checkpoint. We
tested the possible requirement for the phosphorylated form of
NBS1 in Chk1 phosphorylation by using the NBS cells that
were complemented with wild-type NBS1 and the ATM phos-
phorylation site mutant (S343A) NBS1 (Fig. 2C, top panel).
Interestingly, Chk1 expression was up-regulated (5-fold) by
overexpression of S343A mutant NBS1 (Fig. 2C, bottom panel);
however, the dependence of Ser-317 phosphorylation on NBS1
phosphorylation was not clear (Fig. 2C, middle panel). Quan-
tification of data indicated that phosphorylation, relative to the
amount of Chk1 protein, was reduced in S343A-overexpressing
cells.
To test whether activation of Chk1 after IR required a func-
tional ATM protein, we assayed Chk1 activation in ATM-null
FIG. 1. ATM dependence of Chk1 phosphorylation in response to IR. A, Chk1 mobility shift in control and A-T cells in response to IR.
Asynchronously growing cultures were exposed to IR at indicated dosage or UV (50J/m2), and cell lysates were immunoblotted with anti-Chk1
antibody. C3ABR, control lymphoblastoid cell lines; AT1ABR and AT3ABR, AT cell lines. L3 is a lymphoblastoid cell line established from a North
African Jewish A-T patient (obtained from Y. Shiloh). B, in vivo phosphorylation of Chk1 in response to IR. Mock-treated or IR-treated cells were
incubated with 32P-labeled inorganic phosphate. Anti-Chk1 immunoprecipitates were autoradiographed. C, analysis of Chk1 phosphorylation on
Ser-317 after various DNA damaging agents. Total cell lysates were prepared 1 h after treatments as indicated above the lanes and immunoblotted
with an antibody specific for phospho Ser-317 Chk1 (-Chk1 S317P; upper panel) or phospho Ser-15 p53 (-p53 S15P; bottom panel). D, time course
of phosphorylation of Chk1 on Ser-317 in response to IR. Cells were irradiated at 6 Gy, and total cell lysates, prepared at the indicated time points,
were immunoblotted with an antibody specific for phospho Ser-317 Chk1 (-Chk1 S317P; upper panel) or total Chk1 (-Chk1; lower panel). E,
Ser-317 phosphorylation in an ATM-reconstituted AT cell line. ATM-null (AT221JE-T) cells containing either vector alone or vector expressing
ATM were irradiated at 6 Gy and harvested 1 h later. Total cell extracts were probed with anti-Ser-317-Chk1 (-S317P-Chk1; top panel),
anti-total-Chk1 (-Chk1; middle panel), or anti-Ser-15-p53 antibody (-S15P-p53; bottom panel). F, Ser-317 phosphorylation in lymphoblastoid cell
lines from individuals, either homozygous (109II-5 and 109II-6) or heterozygous (109II-3 and 109III-1) for the ATM T7271G mutation. Cells were
exposed to ionizing radiation and harvested 1 h later. Cell extracts were probed with anti-phospho-Ser-317 antibody (-Chk1 S317 P) or anti-total
Chk1 antibody (-Chk1).
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cells complemented with empty vector or vector encoding wild-
type ATM. Treating ATM-null cells with radiation had no effect
on Chk1 activity and, interestingly, cells expressing ATM had
slightly higher basal levels of Chk1 activity compared with
ATM-null cells. IR treatment in the presence of ATM had a
small effect on the activation of Chk1 (Fig. 2D). Similarly, we
studied Chk1 activation after IR in NBS1 defective cells with or
without complementation with NBS1 and failed to observe the
NBS1 dependence of Chk1 activation after IR; however, like
the ATM reconstituted cells, NBS1 reconstituted cells showed
higher basal activity compared with retroviral vector only
(LXIN) transfected cells.
Chk1 and G2/M Checkpoint—To address the functional sig-
nificance of the phosphorylation of Chk1, we mutated Ser-317
and Ser-345 singly or doubly to either alanine or aspartate. The
rationale for generating these mutations was that the alanine
mutants, which cannot be phosphorylated, might not be active
if Chk1 phosphorylation is important for its activity, and the
negatively charged carboxyl group of aspartate may potentially
mimic phosphoserine and would therefore be expected to ex-
hibit similar functions to phosphorylated Chk1. Human embry-
onic kidney 293T cells were transfected with FLAG-tagged
wild-type Chk1, phosphorylation site mutants, and kinase-
dead Chk1 to initially determine whether intrinsic kinase ac-
tivity of Chk1 was altered as a consequence of amino acid
substitution. Thirty-six hours after transfection, cells were ei-
ther left unirradiated or irradiated with 6 Gy of IR. Lysates
were prepared and immunoprecipitated with anti-FLAG anti-
body and analyzed for Chk1 protein and Chk1 kinase activity.
As seen in Fig. 3, each phosphorylation site mutant of Chk1
(both alanine and aspartate) had specific activity quite compa-
rable with wild-type Chk1, whereas kinase dead-Chk1 (D130A)
had negligible activity in this assay. Furthermore, the activity
of the constructs examined above remained unchanged after
treatment with IR (data not shown). These results indicate that
the phosphorylation site mutants of Chk1 do not affect the
intrinsic activity of Chk1 to a great extent.
Earlier studies using small molecule inhibitors of Chk1 (SB-
218078 and UCN-01) have demonstrated a role for Chk1 in the
regulation of the G2/M checkpoint (26, 27). However, it is dif-
ficult to attribute their effects to Chk1 inhibition, as these
inhibitors do inhibit other kinases as well. We therefore chose
to address the requirement for Chk1 in G2 checkpoint signaling
more specifically using an siRNA knockout of Chk1 expression.
HeLa cells were incubated with Chk1-specific siRNA, and the
Chk1 expression was significantly reduced in treated cells (Fig.
4C). Both control and siRNA treated HeLa cells were examined
for their ability to delay in G2 at 1 h after exposure to 6 Gy of
IR by flow cytometric assessment of anti-phospho-histone H3
antibody to distinguish mitotic cells from G2 cells. Control cells
treated with nonspecific siRNA showed a 43–48% decrease in
the number of cells entering mitosis (Fig. 4, A and B). The Chk1
siRNA-treated samples showed no detectable reduction in mi-
totic index following 1 h post IR (Fig. 4, A and B). These results
suggest that Chk1 is required for the delay in mitotic entry
after IR. To determine whether phosphorylation events con-
tributed to G2/M checkpoint regulation by Chk1, we tested
whether an IR-induced G2 checkpoint could be abrogated by
overexpression of alanine phosphorylation site mutants of
Chk1. Wild-type Chk1 and phosphorylation site mutant trans-
fected cells (Ser-317, Ser-345, and double mutations involving
Ser-317 and Ser-345) showed between 80 and 70% reduction in
FIG. 2. NBS1 dependence of Chk1 phosphorylation on Ser-317
in response to IR. A, control (C3ABR), ATM-deficient (L3) and NBS-
deficient cell lines (NBS02 and NBS03) were exposed to 6 Gy of IR and
harvested 1 h later. Cell extracts were probed with anti-phospho Ser-
317 (-S317P-Chk1). B, UV- and HU-induced phosphorylation of Chk1
on Ser-317 does not require functional NBS1. Cells were treated with
various DNA-damaging agents as indicated above the lane and ana-
lyzed by immunoblotting with anti-phospho Ser-317. C, Ser-317 phos-
phorylation in an NBS1-reconstituted NBS-deficient cell line (ILB1).
Cells were transfected with retroviral vector alone (LXIN), full-length
NBS1, or a S343A mutant NBS1 and immunoblotted with anti-NBS1
(top panel), anti-phospho Ser-317 (middle panel), or anti-total Chk1
(bottom panel). D, Chk1 activation in ATM- and NBS1-reconstituted
cells. Cells were untreated or treated with radiation of 6 Gy, and kinase
assays were performed on immunoprecipitated Chk1 using GST-Cdc25
(amino acids 200–256) as a substrate (top panel), and levels of Chk1
were visualized by Western blotting with anti-Chk1 antibody (bottom
panel).
FIG. 3. Protein kinase activity of Chk1 phosphorylation site
mutants. 293T cells were transfected with FLAG-tagged Chk1 wild-
type construct (Wt), S317A mutant, S317A/S345A mutant (AA), S317D/
S345D mutant (DD), and D130A mutant (KD, kinase dead). Lysates
were prepared and immunoprecipitated with anti-FLAG antibody. Pre-
cipitates were tested for their ability to phosphorylate GST-Cdc25C
residues 200–256 (middle and bottom panels showing autoradiographs
after 30 min and 24 h of exposure), and levels of Chk1 wild-type and
various mutants were determined by immunoblotting with anti-FLAG
antibody (top panel). Specific activity of each construct was determined
by quantitating GST-Cdc25C phosphorylation by densitometry and nor-
malizing it to the amount of Chk1 analyzed by immunoblotting with
anti-FLAG.
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the number of mitotic cells. Cells expressing the kinase inactive
Chk1 (D130A and D148E) were also normal in the ability to
delay in G2 following IR. Under the same experimental condi-
tions, expression of kinase-dead ATM showed only a 20% re-
duction in the suppression of mitotic entry after IR. Taken
together, these results show that, although Chk1 is required
for G2 arrest, the precise role, if any, of the phosphorylations at
Ser-317 and Ser-345 in G2 arrest remains to be established.
Chk1 and S Phase Checkpoint—To test whether phosphoryl-
ation of Chk1 on Ser-317 occurred during normal cell cycle
progression, we synchronized HeLa cells at the G1/S boundary
by double thymidine block and followed their progression
through the cell cycle after release into the fresh medium. Chk1
was phosphorylated on Ser-317 at the G1/S boundary and mid
S phase of normal S phase progression; however, no phospho-
rylation was evident in cells in G2 or G2/M (Fig. 5A). In con-
trast, damage-induced phosphorylation of Chk1 on Ser-317 was
observed at all cell cycle stages. Similar results were obtained
with MCF-7 cells synchronized by serum starvation and re-
leased into the fresh medium (data not shown). To determine
whether S phase phosphorylation of Chk1 is also required for
an IR-induced S phase checkpoint, we used U20S cells, which
have been shown previously to be proficient in both branches of
the S phase checkpoint (ATM/NBS1 and ATM/Chk2/Cdc25A
branch). Vector-transfected U2OS cells irradiated at 10 Gy
showed50% inhibition of their DNA synthesis within 1 h post
IR, as monitored by [3H]thymidine incorporation into DNA.
Cells expressing kinase dead Chk1 (D130A) or phospho mutant
Chk1 (S317A, S345A, and S317A/S345A) showed comparable
levels of suppression of DNA synthesis after IR (Fig. 5B). Thus,
these experiments did not show any obvious negative effect of
these mutants on the checkpoint function in the presence of
endogenous Chk1. On the other hand, down-modulation of
endogenous Chk1 by siRNA treatment, followed by IR and
monitoring of the S phase checkpoint, revealed a radiation-
resistant DNA synthesis phenotype (Fig. 5B), a hallmark of
checkpoint failure. Identical results showing the radio-resis-
tant DNA synthesis phenotype were obtained when the activity
of Chk1 was inhibited by the chemical inhibitor UCN01 (data
not shown). Thus, analogous to the requirement of Chk1 for the
activation of the G2/M checkpoint, Chk1 is also essential for the
IR-induced inhibition of DNA synthesis.
FIG. 5. Chk1 regulates IR-induced suppression of DNA synthe-
sis, but phosphorylation site mutants are dispensable. A, cell
cycle-dependent phosphorylation of Chk1 on Ser-317 during the unper-
turbed cell cycle and in response to DNA damage. Cell were synchro-
nized by a double thymidine block and collected at various time points
during the cell cycle as indicated under “Materials and Methods” and
blotted for immunostaining with respective antibodies. B, cells were
transfected with vector alone, Chk1 phosphorylation site mutants
(S317A/S345A), or kinase-dead (KD) Chk1 construct or treated with
siRNA Chk1 oligos. Replicative DNA synthesis was assessed 1 h after
exposure to 10 Gy. Error bars represent the standard deviation of
duplicate samples.
FIG. 4. Chk1 regulates IR-induced
G2/M checkpoint. HeLa cells were
treated with siRNA Chk1 oligos for 48 h.
A, cells were either untreated or irradi-
ated with 6 Gy, then incubated for 1 h,
stained for mitotic index (as described un-
der “Materials and Methods”), and ana-
lyzed by flow cytometry. B, quantitation
of results of three independent experi-
ments described in A. C, Chk1 expression
in cells treated with siRNA Chk1 oligos.
Note that MCM7 expression was used as
control for equal protein loading.
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DISCUSSION
The protein kinase Chk1 is phosphorylated at Ser-317 and
Ser-345 in response to DNA damage. There has been accumu-
lating evidence that these phosphorylation events are regu-
lated by ATR (12–14). ATR shares overlapping substrate spec-
ificities with ATM in vitro, but in vivo it is regulated in
response to different damaging agents. Recent studies have
indicated that, in mammalian cells, ATR and ATM might rep-
resent two parallel branches of the DNA damage response
pathway and that Chk1 and Chk2 in mammals might have
evolved to signal DNA damage from ATR and ATM, respec-
tively (12, 13). The ATM/Chk2 pathway is activated, princi-
pally, by double-stranded DNA breaks, whereas the ATR/Chk1
pathway primarily responds to lesions caused by UV and DNA
replication block. Here we provide evidence for cross-talk be-
tween the two pathways by demonstrating that ATM does
target Chk1 in response to IR. We demonstrate that phospho-
rylation of Chk1 on Ser-317 in response to IR is severely com-
promised in ATM-deficient cells and that ectopic expression of
ATM corrects this defect. However, Chk1 phosphorylation in
response to HU and UV is ATM-independent, possibly cata-
lyzed by ATR, as indicated by earlier studies that have shown
that expression of a kinase-inactive form of ATR interfered
with UV-induced phosphorylation of Chk1 (13, 14).
Our results establish that the NBS1 gene product is required
for optimal IR-induced phosphorylation of Chk1 on Ser-317 but
is dispensable for its phosphorylation in response to HU and
UV. The simplest interpretation of the data is that NBS1 assists
ATM in targeting some of its substrates. This explanation is
consistent with ATM and NBS1 dependence of SMC1 phospho-
rylation in response to IR (23, 24). Normal BRCA1, p53, and
H2AX phosphorylation (16, 28) in NBS1-deficient cells, previ-
ously reported by us and others, suggests that NBS1-independ-
ent mechanisms might promote the phosphorylation of these
substrates by ATM. Notably, p53 and BRCA1 can both be effi-
ciently phosphorylated by ATM in vitro, whereas Chk1 is a poor
ATM substrate in vitro (data not shown).
There has been controversy in the literature as to whether
Chk1 activity is increased after DNA damage; however, after
repeated attempts we have not been able to demonstrate any
consistent increase in activity after IR. Furthermore, we do not
see a defect in Chk1 kinase activation in ATM-deficient or
NBS-deficient cells in response to IR. To understand whether
phosphorylation of Chk1 is required for its checkpoint function,
we overexpressed phosphorylation site mutants of Chk1 either
singly (S317A and S345A) or in combination to study their
effects on G2/M and S phase checkpoint. Both phosphorylation
site mutants were active as a protein kinase with or without
prior exposure to IR. Our results demonstrate that the phos-
phorylation site mutants do not interfere with the checkpoint
control, yet the existence of some additional site(s) of phospho-
rylation in Chk1, potentially capable of mediating the check-
point function, is not very likely given that these two sites of
phosphorylation are the only two Chk1 sites conserved across
other species, including fission yeast, Caenorhabditis elegans,
Xenopus, and Drosophila (13). Furthermore, similar to the
phospho mutants, we were unable to demonstrate a dominant
negative effect through overexpression of kinase-inactive Chk1
(D130A or D148E). These findings raise the possibility that
Chk1 activation does not depend on its dimerization and that
the interactions with its substrates are very dynamic, with a
rapid turnover of interaction. Consequently, the kinase-inac-
tive form of the protein may not be capable of sequestering
targets into non-functional complexes. Thus, it might not be
possible to demonstrate a dominant negative effect of Chk1
phospho mutants in overexpression studies. Therefore, the sig-
nificance of the phosphorylation sites can only be addressed by
comparing the abilities of wild-type and phospho mutant Chk1
to restore the checkpoint functions in Chk1-deficient cells. The
major problem with these experiments is the lack of availabil-
ity of Chk1-null cells, as Chk1 is an essential gene in mice (14,
29). Nevertheless, we have shown that the reduction of Chk1
expression in mammalian cells by siRNA does lead to a defect
in S and G2/M checkpoint control, which is consistent with a
recently published report (30). These Chk1-deficient cells
might be suitable for complementation studies with wild-type
or Chk1 mutant constructs. The challenge here will be to mod-
ify various Chk1 constructs to make them resistant to inhibi-
tion by siRNA, which will be the goal of future experiments.
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